Assessing Lepu Biopharma (SEHK:2157) Valuation After New 2025 Profit Guidance And Dividend Discussion

Simply Wall St.03-15

AdvertisementWhy Lepu Biopharma’s Latest Guidance Matters Lepu Biopharma (SEHK:2157) has drawn fresh attention after issuing earnings guidance that points to at least RMB 200 million in net profit for...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619919488?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-15 23:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619919488","market":"nz","top_or_hot":-1,"title":"Assessing Lepu Biopharma (SEHK:2157) Valuation After New 2025 Profit Guidance And Dividend Discussion","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Lepu Biopharma’s Latest Guidance Matters Lepu Biopharma (SEHK:2157) has drawn fresh attention after issuing earnings guidance that points to at least RMB 200 million in net profit for...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-new-2025-p\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Lepu Biopharma (SEHK:2157) Valuation After New 2025 Profit Guidance And Dividend Discussion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Lepu Biopharma (SEHK:2157) Valuation After New 2025 Profit Guidance And Dividend Discussion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-15 23:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-new-2025-p><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Lepu Biopharma’s Latest Guidance Matters Lepu Biopharma (SEHK:2157) has drawn fresh attention after issuing earnings guidance that points to at least RMB 200 million in net profit for...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-new-2025-p\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-new-2025-p","article_id":"2619919488","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-new-2025-p","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619919488","pubTimestamp":1773587973,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Lepu Biopharma’s Latest Guidance Matters\nLepu Biopharma (SEHK:2157) has drawn fresh attention after issuing earnings guidance that points to at least RMB 200 million in net profit for 2025, compared with a RMB 411 million loss in 2024.\nThe company links this projected swing to revenue from PUYOUHENG and newly approved MEIYOUHENG, expanded licensing income, and a one off reclassification gain on an investment, while an upcoming March 25 board meeting will review the full 2025 results and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02157":"乐普生物-B"},"translate_title":"在新的2025年利润指引和股息讨论后评估乐普生物制药（SEHK：2157）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":0.9},"content_text":"AdvertisementWhy Lepu Biopharma’s Latest Guidance Matters Lepu Biopharma (SEHK:2157) has drawn fresh attention after issuing earnings guidance that points to at least RMB 200 million in net profit for 2025, compared with a RMB 411 million loss in 2024. The company links this projected swing to revenue from PUYOUHENG and newly approved MEIYOUHENG, expanded licensing income, and a one off reclassification gain on an investment, while an upcoming March 25 board meeting will review the full 2025 results and dividend plans. See our latest analysis for Lepu Biopharma. The earnings guidance sits against a share price of HK$4.92, with a 7 day share price return of 12.07% and a 30 day share price return of 6.03%. The 90 day share price return of 9.89% alongside a slightly negative year to date move suggests momentum has picked up only recently. The 1 year total shareholder return of 47.31% contrasts with a 3 year total shareholder return decline of 9.56%, highlighting how sentiment around Lepu Biopharma has shifted as investors absorb the profit outlook and the upcoming March 25 board meeting. If Lepu Biopharma’s update has you thinking about where growth in healthcare could emerge next, you might want to look through our screener of 123 healthcare AI stocks as a way to surface other opportunities. With earnings guidance pointing to a swing into profit and the share price already up strongly over the past year, the real question is whether Lepu Biopharma is still mispriced or whether the market is already factoring in expectations for future growth. Preferred Price-to-Sales of 11.2x: Is It Justified? Lepu Biopharma trades on a P/S of 11.2x, which sits below both the Hong Kong biotechs peer average and the wider industry, even though the shares have already moved sharply over the past year. The P/S ratio compares the company’s market value to its revenue, which matters more than earnings here because Lepu Biopharma is still loss making at the net income level. For biotech names that are investing heavily in pipelines and have uneven profitability, investors often lean on revenue based measures to gauge how much the market is paying for each unit of current sales. Against that backdrop, Lepu Biopharma screens as “good value” relative to the Hong Kong Biotechs industry average P/S of 13.4x and an even higher peer group average of 23.6x. However, when you compare the current 11.2x P/S to an estimated fair P/S of 9.4x, the shares look expensive on this fair ratio benchmark and the market could move closer to that level if sentiment cools. Explore the SWS fair ratio for Lepu Biopharma Result: Price-to-Sales of 11.2x (OVERVALUED) However, you still have to factor in execution risk related to late stage trials and product launches, as well as the company’s recent net income decline of 39.7%. Find out about the key risks to this Lepu Biopharma narrative. Next Steps With sentiment clearly mixed, with both risks and rewards in play, it makes sense to move quickly and look through the numbers yourself. You can see the balance of concerns and potential upsides in our breakdown of 1 key reward and 2 important warning signs. Looking for more investment ideas? If you stop at Lepu Biopharma, you could miss out on other opportunities that fit your style. Use the ideas below as a springboard.  Spot potential turnaround stories early by scanning 234 elite penny stocks with strong financials that already show solid financial footing instead of relying on hype alone. Zero in on quality at a sensible price by reviewing our 229 high quality undervalued stocks and see which names currently line up with stronger fundamentals. Prioritize resilience by checking companies in the 296 resilient stocks with low risk scores and focus on businesses with a calmer risk profile for your watchlist.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619919488","isCrawlerRequest":true}